RT Journal Article
SR Electronic
T1 Palivizumab for the prevention of respiratory syncytial virus infection
JF Canadian Family Physician
JO Can Fam Physician
FD The College of Family Physicians of Canada
SP 769
OP 772
VO 56
IS 8
A1 Rogovik, Alexander L.
A1 Carleton, Bruce
A1 Solimano, Alfonso
A1 Goldman, Ran
YR 2010
UL http://www.cfp.ca/content/56/8/769.abstract
AB QUESTION Palivizumab, a specific monoclonal antibody for respiratory syncytial virus (RSV), is available for prevention of pediatric respiratory tract infections. What are the indications for its use and can it be used for treatment of RSV infections?ANSWER Most infants should not be considered for RSV prophylaxis with palivizumab. The drug is approved for use for different indications in different Canadian provinces. The drug should be administered only in the context of infants most vulnerable to severe RSV illness with a high likelihood of hospital admission, particularly in the first 6 months of life. It is not effective in the treatment of RSV disease and it is not approved or recommended for this indication.